This study aims to evaluate the effect of an AI-assisted expressive writing intervention on anxiety, emotional distress, and quality of life among patients receiving chemotherapy. A mixed-methods, interventional research design will be employed. Participants will be assigned to either a study group receiving the AI-assisted expressive writing program in addition to routine care or a control group receiving routine care only. Quantitative data will be collected using the Depression Anxiety Stress Scale-21 (DASS-21) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Qualitative data will be obtained through semi-structured interviews to explore participants' experiences with the intervention. The findings are expected to provide evidence regarding the effectiveness of AI-assisted expressive writing as a supportive strategy for improving psychological well-being and quality of life among patients undergoing chemotherapy.
Adult patients aged 18 years and above.
Diagnosed with any type of cancer and currently receiving chemotherapy treatment.
Able to read and write Arabic.
Able to communicate and express thoughts and feelings.
Diagnosed with severe psychiatric disorders (e.g., psychosis or schizophrenia).
Having cognitive impairment that interferes with understanding or communication.
Currently receiving structured psychological therapy during the study period.
Unable to complete the study questionnaires or intervention sessions.